Peter Kiener
22Patents
8h-index
29Co-inventors
75Inventor score
Filing activity: May 17, 1989 → May 4, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5122368A | Anthracycline conjugates having a novel linker and methods for their production | Human Necessities | 305 | Expired |
| US5977318A | CTLA4 receptor and uses thereof | Emerging Cross-Sectional Technologies | 151 | Expired |
| US5851795A | Soluble CTLA4 molecules and uses thereof | Emerging Cross-Sectional Technologies | 99 | Expired |
| US5968510A | CTLA4 receptor and uses thereof | Emerging Cross-Sectional Technologies | 88 | Expired |
| US5885579A | CTLA4 receptor and uses thereof | Emerging Cross-Sectional Technologies | 64 | Expired |
| US7658921B2 | Molecules with extended half-lives, compositions and uses thereof | Chemistry; Metallurgy | 56 | Active |
| US8323653B2 | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | Emerging Cross-Sectional Technologies | 22 | Active |
| US7585504B2 | High affinity antibodies against HMGB1 and methods of use thereof | Emerging Cross-Sectional Technologies | 16 | Active |
| US10150800B2 | EGFR-binding modular recognition domains | Emerging Cross-Sectional Technologies | 7 | Active |
| US8137670B2 | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells | Emerging Cross-Sectional Technologies | 7 | Active |
| US9676833B2 | Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof | Chemistry; Metallurgy | 6 | Active |
| US7964706B2 | High affinity antibodies against HMGB1 and methods of use thereof | Chemistry; Metallurgy | 6 | Active |
| US8883992B2 | Humanized anti-CD19 antibodies | Emerging Cross-Sectional Technologies | 3 | Active |
| US8129130B2 | High affinity antibodies against HMGB1 and methods of use thereof | Chemistry; Metallurgy | 3 | Active |
| US8153131B2 | High affinity antibodies against HMGB1 and methods of use thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US6455683B1 | DNA molecules encoding human CLAX proteins and their soluble fusion proteins | Chemistry; Metallurgy | 3 | Expired |
| US9896505B2 | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | Emerging Cross-Sectional Technologies | 2 | Active |
| US9988459B2 | Anti-IFNAR1 antibodies with reduced Fc ligand affinity | Chemistry; Metallurgy | 2 | Active |
| US8404236B2 | Method of identifying membrane Ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells | Emerging Cross-Sectional Technologies | 1 | Active |
| US10301390B2 | Anti-IFNAR1 antibodies with reduced Fc ligand affinity | Chemistry; Metallurgy | 1 | Active |
| US10087222B2 | Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides | Chemistry; Metallurgy | 0 | Active |
| US10526381B2 | Multivalent and monovalent multispecific complexes and their uses | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.